NYSE · Analyst Forecast

Teva Pharmaceutical Industries Limited (TEVA) Stock Forecast & Price Target

$42.62 NYSE: TEVA Market Cap $49.73B

Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 15, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering Teva Pharmaceutical Industries Limited (TEVA), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Teva Pharmaceutical Industries Limited, analysts forecast revenue rising from $16.89B in 2025 to $19.57B in 2030; the average estimate for 2030 earnings per share is $4.13; with published estimates ranging from $4.02 to $4.20; 10 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$42.62
Consensus targetThe average of the price targets analysts have published.$48.22
Median targetThe middle target, less affected by a single outlier.$48.00
Highest targetThe most optimistic published target.$54.00
Lowest targetThe most pessimistic published target.$44.00
Difference from priceHow far the consensus target sits from today’s price.+13.1%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2025$16.84B$16.89B$16.92B9
2026$16.71B$16.78B$16.83B9
2027$17.24B$17.36B$17.45B10
2028$17.27B$18.16B$18.73B10
2029$18.40B$18.78B$19.02B5
2030$19.17B$19.57B$19.83B5

Earnings per share forecast

YearLowAverageHighAnalysts
2025$2.61$2.63$2.679
2026$1.96$2.06$2.279
2027$2.99$3.12$3.4310
2028$3.22$3.50$3.8910
2029$3.66$3.76$3.835
2030$4.02$4.13$4.205

Teva Pharmaceutical Industries Limited (TEVA) forecast — frequently asked questions

What is the analyst price target for Teva Pharmaceutical Industries Limited?

Analysts covering Teva Pharmaceutical Industries Limited (TEVA) have a consensus price target of $48.22, 13.1% above the current price of $42.62. Published targets range from $44.00 to $54.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for Teva Pharmaceutical Industries Limited's earnings?

The average analyst estimate for Teva Pharmaceutical Industries Limited (TEVA) earnings per share in 2030 is 4.13, with individual estimates between 4.02 and 4.20.

How much revenue is Teva Pharmaceutical Industries Limited expected to make?

Analysts forecast Teva Pharmaceutical Industries Limited (TEVA) revenue of $19.57B in 2030, based on 5 published estimates.

How many analysts cover TEVA?

10 analysts contribute estimates for Teva Pharmaceutical Industries Limited (TEVA). Thin coverage makes an average less reliable.

Analyst forecasts for other Drug Manufacturers - Specialty & Generic stocks

ZTS forecastVTRS forecastELAN forecastRDY forecastALKS forecastAMRX forecastLNTH forecastSUPN forecastBHC forecastRGC stockAll Drug Manufacturers - Specialty & Generic stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.